よむ、つかう、まなぶ。
【参考資料２－１】抗微生物薬適正使用の手引き 第四版（案）医科・外来編 (95 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
医科・外来編
81. 国立感染症研究所. 病原体微生物検出情報 ロタウイルス 2018/19～2022/23 シーズン.
https://www.niid.go.jp/niid/ja/iasr/510-surveillance/iasr/graphs/1532-iasrgv.html. 最終閲覧日
2023 年 3 月 24 日.
82. Bhutta Z. Acute Gastroenteritis in Children. Nelson Textbook of Pediatrics: Elsevier;
2016.:p1870.
83. National Institute for Health and Care Excellence (NICE). Diarrhoea and vomiting diagnosis,
assessment and management in children younger than 5 years caused by gastroenteritis.
https://www.ncbi.nlm.nih.gov/books/NBK63844/. 最終閲覧日 2023 年 3 月 24 日.
84. Guarino A, et al. European Society for Pediatric Gastroenterology, Hepatology, and
Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for
the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr
Gastroenterol Nutr. 2014. 59(1):132-52.
85. JaA. The Rational Clinical Examination: Evidence-Based Clinical Diagnosis. McGraw-Hill
Education, LLC; 2009.
86. Tajiri H, et al. A role for fosfomycin treatment in children for prevention of haemolytic-uraemic
syndrome accompanying Shiga toxin-producing Escherichia coli infection. Int J Antimicrob
Agents. 2015. 46(5):586-9.
87. Myojin S, et al. Interventions for Shiga toxin-producing Escherichia coli gastroenteritis and
risk of hemolytic uremic syndrome: A population-based matched case control study. PLoS
One. 2022. 17(2):e0263349.
88. Ikeda K, et al. Effect of early fosfomycin treatment on prevention of hemolytic uremic
syndrome accompanying Escherichia coli O157:H7 infection. Clinical nephrology 1999.
52:357-62.
89. 日本耳科学会／日本小児耳鼻咽喉科学会／日本耳鼻咽喉科免疫アレルギー感染症学会. 小児
急性中耳炎診療ガイドライン 2024 年版. 金原出版; 2024
90. 日本耳科学会／日本小児耳鼻咽喉科学会. 小児滲出性中耳炎診療ガイドライン 2015 年版. 金
原出版; 2015
91. Faden H, et al. Otitis media: back to basics. Pediatr Infect Dis J. 1998. 17:1105-13
92. Kerschner JE, et al. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA: Elsevier; 2016.
chap 640 p3085
93. Lieberthal AS, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013.
131(3):e964-99
94. 佐伯忠彦. 愛媛医学 13 巻 1 号 26-33, 1994.
95. Heikkinen T, et al. Signs and symptoms predicting acute otitis media. Arch Pediatr Adolesc
Med. 1995. 149(1):26-9.
96. Uhari M, et al. Prediction of acute otitis media with symptoms and signs. Acta Paediatr.
1995. 84(1):90-2.
97. Damoiseaux RA, et al. Primary care based randomised, double blind trial of amoxicillin
versus placebo for acute otitis media in children aged under 2 years. BMJ. 2000.
5;320(7231):350-4.
98. Smolinski NE, Djabali EJ, Al-Bahou J, Pomputius A, Antonelli PJ, Winterstein AG. Antibiotic
treatment to prevent pediatric acute otitis media infectious complications: A meta-analysis.
PLoS One. 2024. 19(6):e0304742
99. Venekamp RP, Sanders SL, Glasziou PP, Rovers MM. Antibiotics for acute otitis media in
children. Cochrane Database Syst Rev. 2023. 11(11):CD000219.
95
第四版
医科・外来編
81. 国立感染症研究所. 病原体微生物検出情報 ロタウイルス 2018/19～2022/23 シーズン.
https://www.niid.go.jp/niid/ja/iasr/510-surveillance/iasr/graphs/1532-iasrgv.html. 最終閲覧日
2023 年 3 月 24 日.
82. Bhutta Z. Acute Gastroenteritis in Children. Nelson Textbook of Pediatrics: Elsevier;
2016.:p1870.
83. National Institute for Health and Care Excellence (NICE). Diarrhoea and vomiting diagnosis,
assessment and management in children younger than 5 years caused by gastroenteritis.
https://www.ncbi.nlm.nih.gov/books/NBK63844/. 最終閲覧日 2023 年 3 月 24 日.
84. Guarino A, et al. European Society for Pediatric Gastroenterology, Hepatology, and
Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for
the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr
Gastroenterol Nutr. 2014. 59(1):132-52.
85. JaA. The Rational Clinical Examination: Evidence-Based Clinical Diagnosis. McGraw-Hill
Education, LLC; 2009.
86. Tajiri H, et al. A role for fosfomycin treatment in children for prevention of haemolytic-uraemic
syndrome accompanying Shiga toxin-producing Escherichia coli infection. Int J Antimicrob
Agents. 2015. 46(5):586-9.
87. Myojin S, et al. Interventions for Shiga toxin-producing Escherichia coli gastroenteritis and
risk of hemolytic uremic syndrome: A population-based matched case control study. PLoS
One. 2022. 17(2):e0263349.
88. Ikeda K, et al. Effect of early fosfomycin treatment on prevention of hemolytic uremic
syndrome accompanying Escherichia coli O157:H7 infection. Clinical nephrology 1999.
52:357-62.
89. 日本耳科学会／日本小児耳鼻咽喉科学会／日本耳鼻咽喉科免疫アレルギー感染症学会. 小児
急性中耳炎診療ガイドライン 2024 年版. 金原出版; 2024
90. 日本耳科学会／日本小児耳鼻咽喉科学会. 小児滲出性中耳炎診療ガイドライン 2015 年版. 金
原出版; 2015
91. Faden H, et al. Otitis media: back to basics. Pediatr Infect Dis J. 1998. 17:1105-13
92. Kerschner JE, et al. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA: Elsevier; 2016.
chap 640 p3085
93. Lieberthal AS, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013.
131(3):e964-99
94. 佐伯忠彦. 愛媛医学 13 巻 1 号 26-33, 1994.
95. Heikkinen T, et al. Signs and symptoms predicting acute otitis media. Arch Pediatr Adolesc
Med. 1995. 149(1):26-9.
96. Uhari M, et al. Prediction of acute otitis media with symptoms and signs. Acta Paediatr.
1995. 84(1):90-2.
97. Damoiseaux RA, et al. Primary care based randomised, double blind trial of amoxicillin
versus placebo for acute otitis media in children aged under 2 years. BMJ. 2000.
5;320(7231):350-4.
98. Smolinski NE, Djabali EJ, Al-Bahou J, Pomputius A, Antonelli PJ, Winterstein AG. Antibiotic
treatment to prevent pediatric acute otitis media infectious complications: A meta-analysis.
PLoS One. 2024. 19(6):e0304742
99. Venekamp RP, Sanders SL, Glasziou PP, Rovers MM. Antibiotics for acute otitis media in
children. Cochrane Database Syst Rev. 2023. 11(11):CD000219.
95